CVALF
Price
$1.93
Change
+$0.01 (+0.52%)
Updated
Jul 25 closing price
Capitalization
53.01M
MBIO
Price
$1.91
Change
-$0.12 (-5.91%)
Updated
Jul 25 closing price
Capitalization
8.36M
Interact to see
Advertisement

CVALF vs MBIO

Header iconCVALF vs MBIO Comparison
Open Charts CVALF vs MBIOBanner chart's image
Covalon Technologies
Price$1.93
Change+$0.01 (+0.52%)
Volume$12.43K
Capitalization53.01M
Mustang Bio
Price$1.91
Change-$0.12 (-5.91%)
Volume$277.13K
Capitalization8.36M
CVALF vs MBIO Comparison Chart in %
Loading...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVALF vs. MBIO commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Buy and MBIO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CVALF: $1.93 vs. MBIO: $1.91)
Brand notoriety: CVALF and MBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 236% vs. MBIO: 3%
Market capitalization -- CVALF: $53.01M vs. MBIO: $8.36M
CVALF [@Biotechnology] is valued at $53.01M. MBIO’s [@Biotechnology] market capitalization is $8.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileMBIO’s FA Score has 0 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • MBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, CVALF is a better buy in the long-term than MBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 5 TA indicator(s) are bullish while MBIO’s TA Score has 3 bullish TA indicator(s).

  • CVALF’s TA Score: 5 bullish, 5 bearish.
  • MBIO’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CVALF is a better buy in the short-term than MBIO.

Price Growth

CVALF (@Biotechnology) experienced а +1.58% price change this week, while MBIO (@Biotechnology) price change was -12.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

MBIO is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CVALF($53M) has a higher market cap than MBIO($8.36M). CVALF YTD gains are higher at: -13.839 vs. MBIO (-78.418). CVALF has higher annual earnings (EBITDA): 4.73M vs. MBIO (-10.6M). CVALF has more cash in the bank: 18M vs. MBIO (14.2M). MBIO has less debt than CVALF: MBIO (0) vs CVALF (609K). CVALF has higher revenues than MBIO: CVALF (33.8M) vs MBIO (0).
CVALFMBIOCVALF / MBIO
Capitalization53M8.36M634%
EBITDA4.73M-10.6M-45%
Gain YTD-13.839-78.41818%
P/E Ratio17.50N/A-
Revenue33.8M0-
Total Cash18M14.2M127%
Total Debt609K0-
FUNDAMENTALS RATINGS
CVALF vs MBIO: Fundamental Ratings
CVALF
MBIO
OUTLOOK RATING
1..100
2395
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
55100
PRICE GROWTH RATING
1..100
4838
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (62) in the null industry is in the same range as MBIO (91) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew similarly to MBIO’s over the last 12 months.

CVALF's Profit vs Risk Rating (61) in the null industry is somewhat better than the same rating for MBIO (100) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew somewhat faster than MBIO’s over the last 12 months.

CVALF's SMR Rating (55) in the null industry is somewhat better than the same rating for MBIO (100) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew somewhat faster than MBIO’s over the last 12 months.

MBIO's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as CVALF (48) in the null industry. This means that MBIO’s stock grew similarly to CVALF’s over the last 12 months.

CVALF's P/E Growth Rating (92) in the null industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew similarly to MBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFMBIO
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
66%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
69%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VASO0.13N/A
+1.13%
Vaso Corporation
CNGO23.50N/A
N/A
Cengage Learning Holdings II Inc
FUPPF42.99N/A
N/A
FUCHS SE
NICLF0.09N/A
N/A
Class 1 Nickel and Technologies Limited
KMTUF35.43-1.28
-3.49%
Komatsu Ltd.

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
+0.52%
SMMT - CVALF
27%
Poorly correlated
+3.99%
GNFT - CVALF
25%
Poorly correlated
+3.99%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
-0.30%
MBIO - CVALF
20%
Poorly correlated
-5.91%
More

MBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBIO has been closely correlated with SLRX. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MBIO jumps, then SLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBIO
1D Price
Change %
MBIO100%
-5.91%
SLRX - MBIO
71%
Closely correlated
-0.17%
MDGL - MBIO
50%
Loosely correlated
-0.26%
ORMP - MBIO
44%
Loosely correlated
-3.57%
AXON - MBIO
40%
Loosely correlated
+3.63%
SCNI - MBIO
38%
Loosely correlated
-3.74%
More